Brittany C. Fields

Brittany C. Fields

Auto-generated profile, based on publicly available information

Brittany C. Fields

Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2025 in Annals of Surgery
Verified
Journal Article
Closed access
BFBrittany C. Fields
Brittany C. Fields
JSJose Miguel Soliz
Jose Miguel Soliz
BSBarbra Bryce Do Speer
Barbra Bryce Do Speer
SHShannon Hancher-Hodges
Shannon Hancher-Hodges
KPKeyuri U. Popat
Keyuri U. Popat
TNTimothy E. Newhook
Timothy E. Newhook
Objective: The primary aim was to compare the proportion of opioid-free discharges between 2 postoperative analgesia bundles distinguished by receipt of a single-block versus a second, “rescue” block. Secondary outcomes included differences in discharge prescription oral morphine equivalents (OME) and patient-reported outcomes. Background: After a preoperative quadratus lumborum block, our historical discharge opioid prescription for open pancreatectomy was 300 mg OME, with only 5% patients discharged opioid-free. We hypothesized an opioid-reduction bundle with repeat block on postoperative day (POD)4 could increase opioid-free discharges while reducing symptom burden. Methods: This was a single-institution, unblinded phase II randomized clinical trial, analyzed by intention-to-treat and post hoc Bayesian analyses. Patients undergoing open pancreatectomy were randomized 1:1 to receive a standardized analgesic bundle with or without the addition of the rescue-block on POD4. Results: Among 106 patients randomized (44.3% female; median age 66.5 years; 84% pancreatoduodenectomy; median 5-day stay), 104 completed the trial (52 per arm). By intention-to-treat, 52% of second-block patients were discharged opioid-free versus 36.5% single-block. Median discharge OME was 0 versus 25 mg, respectively. Improved (lower) patient-reported pain and life interference scores were observed in the second-block arm at discharge and 1 month. Conclusions: Addition of a second, “rescue” block to an opioid reduction bundle did not significantly improve opioid-free discharges after open pancreatectomy and was not required to discharge >1/3 of patients opioid-free. Nevertheless, considering improvements in symptom inventory and the high threshold of opioid-free discharge, the concept of a rescue-block to purposefully wean patients to zero use is feasible.

1 December 2025 in JCO Precision Oncology
Verified
Journal Article
Closed access
RAReed I. Ayabe
Reed I. Ayabe
YSY. David Seo
Y. David Seo
BMBrenda Melendez
Brenda Melendez
BFBrittany C. Fields
Brittany C. Fields
LDLaurence P. Diggs
Laurence P. Diggs
JMJessica Maxwell
Jessica Maxwell
PURPOSE: Small bowel neuroendocrine tumors (SBNET) frequently present with metastatic disease, and the efficacy of available systemic therapies, especially immune checkpoint blockade, is limited. Toward developing novel immunomodulatory strategies, we interrogated the tumor immune microenvironment of SBNETs using bulk transcriptional and digital spatial profiling (DSP). METHODS: Patients with SBNET who underwent resection from 2003 to 2016 were retrospectively evaluated. Overall survival (OS) was assessed using the Kaplan-Meier method. The Cox proportional hazards model was used for multivariable analysis (MVA). Bulk transcriptional profiling was performed using the NanoString PanCancer-Immune Panel. Whole human transcriptome DSP was performed using PanCK to segment tumor and adjacent stroma. RESULTS: Unsupervised clustering of gene expression in resected SBNET from 42 patients demonstrated dichotomization by cancer testis antigen (CTA) expression. CTA high patients (12/42, 29%) demonstrated elevated interleukin expression and had significantly improved OS (hazard ratio, 0.211, 95% CI, 0.059 to 0.751). Increased CTA expression was also associated with objective response to atezolizumab/bevacizumab in patients with neuroendocrine tumors ( P = .003). Spatial profiling revealed upregulation of genes involved in immune activation and epigenetic modification in CTA high tumor regions (all P < .05). Immune deconvolution identified a trend toward increased CD8 T cells, NK cell activation, and dendritic cells in CTA high tumor regions, whereas T-cell receptor (TCR) profiling revealed marked differences in TCR segment expression between CTA high and CTA low regions ( P < .001). CONCLUSION: High CTA expression in resected SBNET is independently associated with improved survival. Epigenetic dysregulation and immune activation in CTA-enriched tumor regions highlight the potential for combination epigenetic modifiers and immunotherapy in future trials.

22 June 2026 in Annals of Surgery
Verified
Journal Article
Closed access
BFBrittany C. Fields
Brittany C. Fields
TNTimothy E. Newhook
Timothy E. Newhook
HLHeather A. Lillemoe
Heather A. Lillemoe
AHAnneliese N. Hierl
Anneliese N. Hierl
IRInnocent Rukundo
Innocent Rukundo
CTChing-Wei D Tzeng
Ching-Wei D Tzeng
Background: Standardized prescribing models can reduce discharge opioid prescription and excess pill volumes, mitigating potential opioid dependence and diversion after abdominal operations. This study’s objective was to determine which of 2 validated discharge prescribing models resulted in fewer opioids prescribed and consumed after major abdominal surgery. Methods: This was a pragmatic single-center, phase II randomized clinical trial comparing 2 discharge opioid prescribing models: linear 5x-multiplier algorithm (last-24hrs oral morphine equivalents [OME] times 5) versus capped 3-tier model (5/15/30 pills depending on 0/1-29/≥30 mg OME in last-24hrs). Adults undergoing open abdominal cancer resections by 25 surgeons (5 specialties) were included. A non-opioid analgesic bundle was used perioperatively and at discharge. Co-primary endpoints were discharge opioid volume and 14-day post-discharge consumption. Secondary endpoints included patient satisfaction and symptom inventory. The power (80%) calculation was performed using the two-sample t-test to detect a mean difference in OME with 0.05 significance (0.025 per co-primary outcomes). Results: From April-December 2024, 150 patients (52% female; median age 63) were randomized: 73 to 5x-multiplier; 77 to 3-tier model. Operations included hepatectomy (32%), pancreatectomy (29%), nephrectomy (13%), thoracoabdominal sarcoma resection (15%), and ovarian cytoreduction (11%). Median discharge OME was 25 mg (5x-multiplier) versus 75mg (3-tier, P <0.001), with 44% of 5x-multiplier patients discharged opioid-free (1% in 3-tier). Median post-discharge 14-day opioid consumption was 0mg (5x-multiplier) versus 10 mg (3-tier, P =0.496). Refill rates were 24% (5x-multiplier) versus 18% (3-tier, P =0.426), consistent with historical rates, with no differences in satisfaction or symptom inventory scores. Conclusion: The 5x-multiplier algorithm resulted in fewer prescribed discharge opioids with similar 14-day consumption, refill rates, and satisfaction, compared to a 3-tier model after intra-abdominal cancer surgery.

12 July 2024 in The American Journal of Dermatopathology
Verified
Journal Article
Closed access
BFBrittany C. Fields
Brittany C. Fields
AJAnish J. Jain
Anish J. Jain
VPVictor G. Prieto
Victor G. Prieto
SFSpencer J. Frink
Spencer J. Frink
AHAshley M. Holder
Ashley M. Holder
A 45-year-old woman with a history of previously treated left plantar foot melanoma presented with a left thigh mass. Fine needle aspiration findings were concerning for metastatic melanoma (MM). Imaging was remarkable for PET-avidity of both the biopsied thigh mass and of a left posterior knee nodule. The knee nodule was also enhancing on MRI, concerning for a site of metastasis. Resection of the thigh mass and intra-articular nodule was performed. The thigh lesion was positive for MM. The specimen obtained from the knee demonstrated a proliferation of spindle and epithelioid cells associated with focal fibrosis and scattered giant cells with brown pigment, raising the possibility of melanoma metastasis with treatment effect. Additional immunohistochemical studies with anti-SOX10 failed to demonstrate melanoma cells in the lesion. The final diagnosis for the knee nodule was pigmented villonodular synovitis. This case highlights the potential for pigmented villonodular synovitis to mimic MM, requiring additional pathologic analysis to yield an accurate diagnosis.

1 May 2025 in Advances in Cancer Education and Quality Improvement
Verified
Journal Article
Open access
PDF file
BFBrittany Fields
Brittany Fields
TNTimothy E. Newhook
Timothy E. Newhook
HLHeather Lillemoe
Heather Lillemoe
WQWei Qiao
Wei Qiao
JKJose Karam
Jose Karam
CTChing-Wei D Tzeng
Ching-Wei D Tzeng
Background Surgeons provide up to 10% of total opioid prescriptions across all specialties, and more than one-third of surgeon-prescribed medications are opioids. Patient-reported opioid consumption and risk of persistent opioid use beyond the postoperative recovery period correlate with the initial opioid quantity prescribed at discharge. Interventions to reduce postoperative opioid prescribing have demonstrated no adverse effects on pain control or increased need for prescription refill; however, in the absence of standardized prescription protocols, opioid prescribing practices vary widely. Objective The study objective is to identify the opioid prescribing model that provides the lowest oral morphine equivalents (OME) volume prescribed at discharge and OME consumed in the 14 days after discharge, with no adverse effect on refills and patient quality of life or satisfaction. Methods and Analysis This is a pragmatic single-center, multispecialty, double-arm phase II randomized clinical trial of two discharge opioid prescribing models. All adult (≥18 years) patients who undergo any one of five open abdominal oncologic operations (pancreatectomy, hepatectomy, retroperitoneal sarcoma resection, nephrectomy, or cytoreductive surgery for ovarian cancer) with curative intent and have a planned postoperative inpatient stay of at least 48 hours will be eligible. Patients will be stratified by their managing clinical service and randomized to receive a discharge opioid prescription based on either the 5x-multiplier algorithm or the 3-tier model. The co-primary outcomes are initial discharge OME volume and OME consumption in the 14 days after hospital discharge. Secondary outcomes include rates of patients with zero OME at discharge; rates of refill requests and completions, number of unused or leftover pills, persistent opioid use, and patient-reported quality-of-life metrics at various follow-up times; patient, prescriber, and oncologic factors predictive of persistent opioid use; and patient satisfaction. Each co-primary endpoint will be analyzed using two-sample t-test to compare means and linear regression models to assess differences between the two arms. Ethics and Dissemination This study was approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center (2023-0818). The study will evaluate the difference in initial discharge OME volume and in 14-day post-discharge OME consumption between two discharge opioid prescribing models. Upon completion of the data collection and analyses, a manuscript describing the study results will be submitted to a peer-reviewed journal for publication and dissemination. Trial Registration Number: NCT06232577.

1 May 2025 in Advances in Cancer Education and Quality Improvement
Verified
Journal Article
Open access
PDF file
BFBrittany C. Fields
Brittany C. Fields
TNTimothy E. Newhook
Timothy E. Newhook
HLHeather A. Lillemoe
Heather A. Lillemoe
JMJessica Maxwell
Jessica Maxwell
JSJose Miguel Soliz
Jose Miguel Soliz
CTChing-Wei D Tzeng
Ching-Wei D Tzeng
Background and Objectives We previously reported that implementation of a department-wide opioid education program led to post-education improvements in opioid perceptions and prescription recommendations, with one-month and one-year retention. With ongoing programmatic and quality improvement efforts, we sought to re-evaluate the retention of these improvements five years after initial efforts. Methods Attending surgeons, clinical fellows, and advanced practice providers were surveyed five years after implementation of a comprehensive, departmental opioid reduction framework in August 2018. This framework initially consisted of dedicated opioid education sessions and retrospective assessment of prescribing practices, and subsequently expanded over time to include prospective quality improvement and implementation studies, as well as integration of opioid stewardship measures into usual clinical care. Providers’ perceptions of expected pain scores, opioid requirements, and ideal prescribing habits were assessed with the same survey administered at 1-month (2018) and 1-year post-initial education (2019). Results Eighty-seven of 162 (53.7%) providers responded to the follow-up survey. More providers expressed strong agreement with the statement, “After an inpatient procedure, a patient who has not required opioids for 24 hours before discharge should not receive a discharge opioid prescription.” Significant decreases in the number of opioid pills providers would prescribe at discharge for five sample operations were also observed between 2018-2023. Stepwise decreases in opioid volume prescribed in both inpatient and outpatient settings were reported since the initial 2018 education sessions. Conclusions Dedicated department-wide opioid education, ongoing quality improvement and prospective evaluation, and integration of opioid stewardship into clinical practice were associated with sustained improvement over five years in perceptions of postoperative pain management and decreased discharge opioid prescription recommendations.